NASDAQ:PDEX - Pro-Dex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$15.5162 -0.12 (-0.77 %)
(As of 02/19/2019 11:52 AM ET)
Previous Close$15.64
Today's Range$15.2651 - $15.88
52-Week Range$6.05 - $16.15
Volume19,881 shs
Average Volume34,541 shs
Market Capitalization$64.28 million
P/E Ratio28.58
Dividend YieldN/A
Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services. The company offers its products under the name of Pro-Dex.Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Receive PDEX News and Ratings via Email

Sign-up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:PDEX



Sales & Book Value

Annual Sales$22.47 million
Cash Flow$0.7532 per share
Book Value$4.10 per share


Net Income$1.62 million


Market Cap$64.28 million
OptionableNot Optionable

Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions

What is Pro-Dex's stock symbol?

Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."

How were Pro-Dex's earnings last quarter?

Pro-Dex Inc (NASDAQ:PDEX) announced its quarterly earnings results on Thursday, August, 30th. The medical instruments supplier reported $0.22 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.06 by $0.16. Pro-Dex had a return on equity of 18.26% and a net margin of 12.64%. View Pro-Dex's Earnings History.

When is Pro-Dex's next earnings date?

Pro-Dex is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for Pro-Dex.

Has Pro-Dex been receiving favorable news coverage?

Media headlines about PDEX stock have been trending positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pro-Dex earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.

Who are some of Pro-Dex's key competitors?

Who are Pro-Dex's key executives?

Pro-Dex's management team includes the folowing people:
  • Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 58)
  • Mrs. Alisha K. Charlton, CFO & Corp. Sec. (Age 49)
  • Mr. Phillip S. Brown, VP & GM of OMS
  • Angel Rebamontan Domingo, Director of Regulatory Affairs & Quality Assurance

Who are Pro-Dex's major shareholders?

Pro-Dex's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Alambic Investment Management L.P. (1.67%), Acadian Asset Management LLC (0.98%), Dimensional Fund Advisors LP (0.37%), BlackRock Inc. (0.29%), FNY Investment Advisers LLC (0.26%) and Macquarie Group Ltd. (0.08%). Company insiders that own Pro-Dex stock include Alisha Charlton, David Hovda, Kirk Richard Lee Van Jr, Nicholas John Swenson, Raymond E Cabillot and William James Farrell III. View Institutional Ownership Trends for Pro-Dex.

Which major investors are selling Pro-Dex stock?

PDEX stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd.. Company insiders that have sold Pro-Dex company stock in the last year include Alisha Charlton, David Hovda, Kirk Richard Lee Van Jr, Nicholas John Swenson and Raymond E Cabillot. View Insider Buying and Selling for Pro-Dex.

Which major investors are buying Pro-Dex stock?

PDEX stock was purchased by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P., Dimensional Fund Advisors LP, Acadian Asset Management LLC, FNY Investment Advisers LLC and BlackRock Inc.. View Insider Buying and Selling for Pro-Dex.

How do I buy shares of Pro-Dex?

Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pro-Dex's stock price today?

One share of PDEX stock can currently be purchased for approximately $15.5162.

How big of a company is Pro-Dex?

Pro-Dex has a market capitalization of $64.28 million and generates $22.47 million in revenue each year. Pro-Dex employs 80 workers across the globe.

What is Pro-Dex's official website?

The official website for Pro-Dex is

How can I contact Pro-Dex?

Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3200 or via email at [email protected]

MarketBeat Community Rating for Pro-Dex (NASDAQ PDEX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  66 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about Pro-Dex and other stocks. Vote "Outperform" if you believe PDEX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDEX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by Staff

Featured Article: Tariff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel